South Korea pharma news in brief

27 April 2015

Kim Ok-Yeon, chairperson of the KRPIA, South Korea’s research-based pharmaceutical industry association, pointed out, regarding to the Pharma 2020 Vision announced by the government in 2012, that local pharmaceutical companies face significant difficulties in procuring competitiveness in overseas markets.

Ms Kim commented that pharmaceutical companies are unable to receive proper prices from the government for even high-quality drugs in the current NHI (National Health Insurance) drug price system. In addition, she added the current NHI system must be resolved as it is obstructing the industry’s expansion overseas and limiting growth.

Local drugmakers spend less than global companies on R&D

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK